BioLife Solutions (BLFS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Voting matters and shareholder proposals
Election of seven directors, with nominees including Roderick de Greef, Joydeep Goswami, Amy DuRoss, Rachel Ellingson, Timothy L. Moore, Cathy Coste, and Tony Hunt.
Advisory vote to approve the compensation of named executive officers.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Proxies may vote on other business arising at the meeting or any adjournments.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Annual meeting to be held virtually on August 20, 2025, at 9:00 AM PDT.
Executive compensation and say-on-pay
Advisory vote scheduled for shareholder approval of executive compensation practices.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioLife Solutions
- Achieved $96M revenue and 65% gross margin in FY 2025, driving growth in cell therapy tools.BLFS
Investor presentation5 Mar 2026 - 2025 revenue rose 29% with margin gains; 2026 targets 17–20% growth and profitability.BLFS
Q4 202526 Feb 2026 - Raised 2024 guidance after sequential revenue growth and margin expansion post-divestiture.BLFS
Q2 20242 Feb 2026 - Q3 revenue up 30% with strong Cell Processing growth, margin gains, and SciSafe divestiture.BLFS
Q3 202414 Jan 2026 - Record margins and cash in 2024 set the stage for robust double-digit growth in 2025.BLFS
Q4 20242 Dec 2025 - Annual meeting to elect directors, approve pay, and ratify auditor amid strong 2024 results.BLFS
Proxy Filing1 Dec 2025 - Board recommends all proposals; no executive bonuses for 2023; focus on equity-based incentives.BLFS
Proxy Filing1 Dec 2025 - Internal control remediation, SOX compliance, and board oversight are key priorities for 2024.BLFS
Proxy Filing1 Dec 2025 - Q2 2025 revenue up 29% year-over-year; guidance raised, but net loss deepened on PanTHERA expense.BLFS
Q2 202523 Nov 2025